<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04710407</url>
  </required_header>
  <id_info>
    <org_study_id>SPR994-108</org_study_id>
    <nct_id>NCT04710407</nct_id>
  </id_info>
  <brief_title>Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers</brief_title>
  <official_title>A Phase 1, Single-center, Open-label Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spero Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spero Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the intrapulmonary pharmacokinetics (PK), including ELF and AM concentrations, of&#xD;
      SPR859 (tebipenem) compared to plasma concentrations of SPR859 (tebipenem) (the active moiety&#xD;
      in plasma of the prodrug SPR994) in nonsmoking healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2020</start_date>
  <completion_date type="Actual">March 10, 2021</completion_date>
  <primary_completion_date type="Actual">March 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma PK and lung penetration of SPR859 following multiple doses</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>Plasma PK parameters will include the area under the curve (AUC) from time zero to the last quantifiable sample (AUC0-t), AUC from time zero to end of dosing interval (AUC0-8). The AUC0-8 values for ELF and AM will be determined. The ratios of the AUC0-8 of ELF to the AUC0-8 of plasma and the AUC0-8 of AM to the AUC0-8 of plasma will be calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma PK and lung penetration of SPR859 following multiple doses</measure>
    <time_frame>Day 1 to Day 3</time_frame>
    <description>Plasma PK parameters will include the maximum concentration (Cmax), minimum concentration (Cmin), time to Cmax (tmax), and the terminal-phase half-life (t1/2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability, including adverse events (AEs)</measure>
    <time_frame>Day 1 to Day 10</time_frame>
    <description>Frequency of adverse events by severity, seriouness, system organ class, preferred term and treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability, including clinically significant changes from baseline in clinical laboratory values</measure>
    <time_frame>Day 1 to Day 10</time_frame>
    <description>Change from baseline in selected laboratory assays including WBC, hemoglobin, platelet count, liver function tests (AST, ALT, AP), blood urea nitrogen (BUN), serum creatinine (Cr), and estimated Cr clearance (based on Cockcroft-Gault formula), by treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability, including physical examination</measure>
    <time_frame>Day 1 to Day 10</time_frame>
    <description>Change from baseline in vital signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability, including ECG</measure>
    <time_frame>Day 1 to Day 10</time_frame>
    <description>Cardiac (12-Lead ECG) will be summarized at each scheduled time point using descriptive statistics</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>TBPM-PI-HBr</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects meeting eligibility criteria will receive a total of five doses of TBPM-PI-HBr 600 mg orally every 8 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TBPM-PI-HBr</intervention_name>
    <description>TBPM-PI-HBr (2 x 300mg tablets) a total of five doses</description>
    <arm_group_label>TBPM-PI-HBr</arm_group_label>
    <other_name>TBPM-PI-HBr oral capsule</other_name>
    <other_name>SPR994</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males or female subjects, between 18 and 55 years of age (both inclusive) at the&#xD;
             time of screening&#xD;
&#xD;
          -  BMI ≥ 18.5 and ≤ 32 (kg/m2) and weight between 55.0 and 100.0 kg (both inclusive)&#xD;
&#xD;
          -  Willing and able to provide written informed consent; Willing and able to comply with&#xD;
             all study assessments and adhere to the protocol schedule&#xD;
&#xD;
          -  Medically healthy without clinically significant abnormalities as assessed by the&#xD;
             Investigator based on screening medical history, physical examination, vital signs,&#xD;
             12-lead ECG, hematology, biochemistry and urinalysis&#xD;
&#xD;
          -  Have suitable venous access for blood sampling&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of seizure disorders&#xD;
&#xD;
          -  Positive urine drug, alcohol or cotinine testing at screening or check-in (Day -1)&#xD;
&#xD;
          -  Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg) or hepatitis C antibodies (HCV);&#xD;
&#xD;
          -  Positive testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at&#xD;
             screening;&#xD;
&#xD;
          -  Presence of the following symptoms at screening or within 14 days prior to screening&#xD;
             or Check-in (Day -1)&#xD;
&#xD;
               1. Fever, chills or sweats (temperature of 38 °C / 100.4 °F or higher)&#xD;
&#xD;
               2. Difficulty breathing&#xD;
&#xD;
               3. Cough&#xD;
&#xD;
               4. Sore throat&#xD;
&#xD;
               5. New or recent loss of taste or smell&#xD;
&#xD;
               6. Nausea, vomiting or diarrhea;&#xD;
&#xD;
          -  Close contact with anyone who tested positive for SARS-CoV-2 infection within 14 days&#xD;
             prior to screening or Check-in (Day -1);&#xD;
&#xD;
          -  Electrocardiogram (ECG) with QTcF interval duration equal or greater than 450 msec for&#xD;
             males and 470 msec for females&#xD;
&#xD;
          -  Subjects who have any of the following abnormalities on laboratory values at screening&#xD;
             or prior confinement including:&#xD;
&#xD;
               1. White blood cell count &lt; 3,000/mm3, hemoglobin &lt; 11g/dL;&#xD;
&#xD;
               2. Absolute neutrophil count &lt;1,200/mm3, platelet count &lt;120,000/mm3;&#xD;
&#xD;
               3. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than&#xD;
                  1.5 x the upper limit of normal (ULN) for the reference laboratory;&#xD;
&#xD;
          -  History of substance abuse or alcohol abuse&#xD;
&#xD;
          -  Use of tobacco/nicotine- or marijuana-containing products (including vaping products)&#xD;
             within 12 months prior to screening;&#xD;
&#xD;
          -  Known history of clinically significant hypersensitivity reaction or anaphylaxis to&#xD;
             any medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Baratz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pulmonary Associates</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pulmonary Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>TBPM-PI-HBr</keyword>
  <keyword>tebipenem</keyword>
  <keyword>alveolar macrophages (AM)</keyword>
  <keyword>epithelial lining fluid (ELF)</keyword>
  <keyword>intrapulmonary</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

